U S clinical trials begin for twice yearly HIV prevention injection [Video]

U.S. clinical trials begin for twice-yearly HIV prevention injection
Studies will focus on priority populations underrepresented in HIV clinical research.
What
Two clinical trials have launched to examine a novel long-acting form of HIV pre-exposure prophylaxis (PrEP) in cisgender women and people who inject drugs. The mid-stage studies will assess the safety, acceptability, and pharmacokinetics (how a drug moves through the body) of lenacapavir, an antiretroviral drug administered by injection every six months. The studies are sponsored and funded by Gilead Sciences, Inc., and implemented through the HIV Prevention Trails Network (HPTN). The HPTN is supported by grants from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID), with scientific collaboration on this study and others from the National Institute on Drug Abuse (NIDA) as well as co-funding from NIDA and other NIH institutes.
Thank you for watching the video, wish you health and happiness!
Subscribe to the channel at: https://goo.gl/iz6xA4
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
If you have any questions, please contact us by email: [email protected]
Sincerely thank you!
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Sign up: https://www.youtube.com/channel/UCdLXU6DmZkr-wut3ijU7acg
Facebook: https://www.facebook.com/hivaids2024/
Twitter: https://twitter.com/DauBenh
Gmail: [email protected]